Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2026

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Search results for

There are 22,425 results that match your search.22,425 results
  • The Andean Pact member states have long been viewed as a backwater in the technology field. But, reports James Nurton, the new Decision 486 should radically improve patent protection and transform that image
  • January 1 2000, as for many developing countries, was an important date in India’s diary. It marked the end of the country’s five-year transition period and the moment it became subject to the TRIPs agreement. Tabitha Parker spoke to two senior industry figures about the change
  • The decision of the Court of Appeal in Douglas & Others v Hello Ltd has been heralded as having recognized a right of privacy in English law. Stephen Bate and Lawrence Abramson analyze the decision and its implications
  • Internet and e-commerce allow an entrepreneur to develop sales schemes of its products and services with a never previously imagined territorial scope and extension. Direct selling is both attractive and advantageous. E-commerce requires in some cases, therefore, the adjustment and of course, the amendment of some clauses of commercial inter-mediation contracts, either distribution, agency, licence, supply or franchise contracts.
  • Nearly a decade after the first release of shocking advertising images by Benetton, the German Federal Constitutional Court has now found the ads acceptable. Henning Hartwig examines the landmark decision, which has finally put an extensive discussion to rest
  • Fact they say is stranger than fiction. In the David v Goliath case that is Trovan v Pfizer this is certainly true. In the story David slays Goliath and is proclaimed king. In the Trovan case, Pfizer´ s Goliath is made of stronger stuff. On January 11, Trovan filed an appeal in the Ninth Circuit Court challenging an earlier ruling which overturned a record $143 million damages award to the company for infringement of its Trovan trade mark.
  • With TRIPs compliance, legislative reform and a booming technology market, 2000 was a busy year for patent owners in the emerging markets. MIP writers reveal the results of our annual survey and profile some of the interesting stories from the past year
  • On November 29 2000, a majority of the United States Court of Appeals for the Federal Circuit, sitting en banc, rendered an opinion in Festo Corp v Shoketsu Kogyo Kabushiki Co, published at 56 USPQ 2d 1865, which effectively extinguishes the application of the doctrine of equivalents to any term of a patent claim that was narrowed by amendment during its prosecution before the US Patent and Trademark Office (USPTO). While the majority opinion does purportedly limit the prosecution estoppel created by amendments that narrow a claim in any respect to those amendments made for reasons "related to patentability" , that opinion is also unequivocally clear in holding that any narrowing amendment to a claim term made for "any reason affecting the issuance of a patent" (56 USPQ 2d at 1870-1871) is "related to patentability" whether made voluntarily or in response to a rejection. Specific mention is made of amendments made for reasons based on 35 USC § § 101 and 112, as well as for prior art reasons based on 35 USC § § 102 and 103 as giving rise to prosecution estoppels and thus foreclosing application of the doctrine of equivalents to amended terms or expressions in claims. The majority opinion leaves an apparent escape hatch from estoppel for narrowing claim amendments made for reasons other than patentability, provided each such reason is stated in the prosecution record at the time of the narrowing amendment but this is of very little practical effect because reasons for narrowing amendments to claims that do not somehow implicate patentability are extremely hard to conceive of, much less substantiate. The majority opinion is explicit in holding that: "When a claim amendment creates prosecution history estoppel with regard to a claim element, there is no range of equivalents available for the amended claim element. Application of the doctrine of equivalents to the claim element is completely barred" (56USPQ2d at 1872).
  • The landmark decision of Genelabs Diagnostics Pte Ltd and Nagase Singapore (Pte) Ltd v Institut Pasteur and Pasteur Sanofi Diagnostics (Civil Appeal No 14 of 2000) was the first patent infringement case involving a biotechnology patent to be heard and litigated in Singapore. In a judgment delivered by Justice of Appeal Chao Hick Tin, the Court of Appeal dealt with the validity and infringement of a patent on the HIV-2 virus. Facts of the case
  • Asia has turned the corner in addressing IP deficiencies. But problems remain – from the political wranglings in Indonesia to the booming Korean market. Tabitha Parker investigates